Clene Inc. (CLNN) — SEC Filings
Clene Inc. (CLNN) — 49 SEC filings. Latest: 8-K (May 4, 2026). Includes 33 8-K, 6 10-Q, 5 SC 13G/A.
Overview
Clene Inc. (CLNN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 3, 2025: Clene Inc. filed an 8-K on December 3, 2025, reporting other events and financial statements. The company, formerly known as Chelsea Worldwide Inc. until August 27, 2020, is incorporated in Delaware and headquartered in Salt Lake City, Utah. The filing does not disclose specific financial figures or
Sentiment Summary
Across 49 filings, the sentiment breakdown is: 4 bearish, 45 neutral. The dominant filing sentiment for Clene Inc. is neutral.
Filing Type Overview
Clene Inc. (CLNN) has filed 33 8-K, 6 10-Q, 2 10-K, 2 SC 13G, 5 SC 13G/A, 1 SC 13D/A with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (49)
Risk Profile
Risk Assessment: Of CLNN's 39 recent filings, 3 were flagged as high-risk, 18 as medium-risk, and 18 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $15K |
| Net Income | -$8.777M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $7.925M |
| Operating Margin | -37653.3% |
| Total Assets | $22.311M |
| Total Debt | $34.668M |
Key Executives
- David J. Matlin
Industry Context
Clene Inc. operates in the biotechnology and pharmaceutical sector, a highly competitive and capital-intensive industry. Success often depends on significant R&D investment, clinical trial outcomes, and regulatory approvals. The industry faces constant pressure to innovate while managing high operational costs and navigating complex regulatory landscapes.
Top Tags
filing (7) · 8-K (7) · financials (6) · corporate-update (5) · sec-filing (4) · warrants (4) · regulatory-filing (4) · financial-reporting (3) · corporate-filing (3) · material-definitive-agreement (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (Q3 2025) | $8.777M | Increased from $7.986M in Q3 2024 |
| Net Loss (YTD Q3 2025) | $16.947M | Improved from $25.851M in YTD Q3 2024 |
| Cash and Cash Equivalents | $7.925M | As of September 30, 2025, down from $12.155M at Dec 31, 2024 |
| Accumulated Deficit | $299.1M | As of September 30, 2025, up from $282.1M at Dec 31, 2024 |
| Net Cash Used in Operating Activities | $13.747M | For the nine months ended September 30, 2025 |
| Total Revenue (Q3 2025) | $15K | Decreased from $87K in Q3 2024 |
| Research and Development Expenses (YTD Q3 2025) | $8.508M | Decreased from $14.490M in YTD Q3 2024 |
| Common Shares Outstanding | 10,333,980 | As of November 10, 2025 |
| SEC File Number | 001-39834 | Identifies the company's filing with the SEC. |
| IRS Employer Identification No. | 85-2828339 | Tax identification number for the company. |
| Net Loss (Q2 2025) | $7.4M | Increased from $6.8M in Q2 2024, indicating continued unprofitability. |
| Net Loss (H1 2025) | $8.2M | Significant improvement from $17.9M in H1 2024, primarily due to reduced R&D. |
| Total Revenue (Q2 2025) | $27K | Decreased from $91K in Q2 2024, showing a decline in product and royalty revenue. |
| Total Revenue (H1 2025) | $108K | Decreased from $164K in H1 2024, reflecting overall revenue contraction. |
| Operating Expenses (Q2 2025) | $5.9M | Reduced from $7.5M in Q2 2024, driven by cost-saving initiatives. |
Frequently Asked Questions
What are the latest SEC filings for Clene Inc. (CLNN)?
Clene Inc. has 49 recent SEC filings from Jan 2024 to May 2026, including 33 8-K, 6 10-Q, 5 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CLNN filings?
Across 49 filings, the sentiment breakdown is: 4 bearish, 45 neutral. The dominant sentiment is neutral.
Where can I find Clene Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Clene Inc. (CLNN) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Clene Inc.?
Key financial highlights from Clene Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CLNN?
The investment thesis for CLNN includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Clene Inc.?
Key executives identified across Clene Inc.'s filings include David J. Matlin.
What are the main risk factors for Clene Inc. stock?
Of CLNN's 39 assessed filings, 3 were flagged high-risk, 18 medium-risk, and 18 low-risk.
What are recent predictions and forward guidance from Clene Inc.?
Forward guidance and predictions for Clene Inc. are extracted from SEC filings as they are enriched.